| OPPOSITION | - 32c-Annotated sequence of AMG701 (=SEQ ID NO.661 of the Opposed Patent) | - |
| OPPOSITION | - Anonymous, "A Study of WVT078 in Patients With Multiple Myeloma (MM)", Clinical Trials, (20191009), pages 1 - 9, Clinical Trials, URL: https://clinicaltrials.gov/study/NCT04123418?tab=history&a=1#versioncontent-panel, (2024112024), XP093241147 | - |
| OPPOSITION | - Anonymous, "A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma", Clinical Trials, (20170915), pages 1 - 12, Clinical Trials, URL: https://clinicaltrials.gov/study/NCT03287908?tab=history&a=1#versionconte%20D12%20nt-panel, (20240910), XP093241102 | - |
| OPPOSITION | - Anonymous, "A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma ", Clinical Trials, (20171013), pages 1 - 17, Clinical Trials, URL: https://clinicaltrials.gov/study/NCT03287908?tab=history&a=2%2523version-content-panel, (20250120), XP093241190 | - |
| OPPOSITION | - Anonymous, "CAS Registry AMG-420 / Pacanalotamab ", REGISTRY , (20181206), Database accession no. 2251756-52-0, URL: STN, XP093241547 | - |
| OPPOSITION | - Anonymous, "CAS Registry: AM G-701", REGISTRY , (20181130), Database accession no. 2250292-39-6 , URL: STN, XP093241202 | - |
| OPPOSITION | - Anonymous, "Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispeci^c Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)", Clinical Trials, (20170508), pages 1 - 12, Clinical Trials, URL: https://clinicaltrials.gov/study/NCT03145181?tab=history&a=1#versioncontent-panel, (20240910), XP093241126 | - |
| OPPOSITION | - Anonymous, "Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers ", FDA Guidance for Industry, (20050701), pages 1 - 30, XP093241533 | - |
| OPPOSITION | - Anonymous , Fda, "Blincyto (blinatumomab)", FDA, (20140101), pages 1 - 51, XP093241646 | - |
| OPPOSITION | - Anonymous, "First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)", Clinical Trials, (20190905), pages 1 - 10, Clinical Trials , URL: https://clinicaltrials.gov/study/NCT03287908?tab=history&a=1#versionconte%20D12%20nt-panel, (20240910), XP093241142 | - |
| OPPOSITION | - Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION - TECVAYLI- teclistamab", FDA Label, (20221001), pages 1 - 31, XP093105568 | - |
| OPPOSITION | - Anonymous , "History of Changes for Study: NCT03933735 A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma", Clinical Trials, (20190429), pages 1 - 8, XP093241679 | - |
| OPPOSITION | - Anonymous, "PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma", Clinical Trials, (20170829), pages 1 - 10, Clinical Trials, URL: https://clinicaltrials.gov/study/NCT03269136?tab=history&a=1#version-content-panel, (20240910), XP093241107 | - |
| OPPOSITION | - Anonymous, "Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma (LINKER-MM1)", Clinical Trials, (20181129), pages 1 - 10, Clinical Trials, URL: https://clinicaltrials.gov/study/NCT03761108?tab=history&a=1#versioncontent-panel, (20240910), XP093241137 | - |
| OPPOSITION | - Anonymous, "Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma", Clinical Trials, (20180330), pages 1 - 12, Clinical Trials, URL: https://www.clinicaltrials.gov/study/NCT03486067?tab=history&a=1#versioncontent-panel, (20240910), XP093241111 | - |
| OPPOSITION | - Cho S -F; Lin L; Xing L; Wen K; Yu T; Hsieh P A; Li Y; Munshi N C; Wahl J; Matthes K; Anderson K C; Chapman-Arvedson T; Tai Y -T, "AMG701 potently induces anti-multiple myeloma (MM) functions of T cells and IMiDs further enhance its efficacy to prevent MM relapse in vivo", Blood, US , (20191101), vol. 134, no. Supplement 1, ISSN 1528-0020, pages 1 - 6, XP009519986 | - |
| OPPOSITION | - D24- EP 19 208 417.6, priority application to the Opposed Patent | - |
| OPPOSITION | - D31-Epitope mapping data fur AMG701 | - |
| OPPOSITION | - D32a-Sequence comparison of AMG701 and SEQ ID NO:661 of the Opposed Patent | - |
| OPPOSITION | - D32b-Sequence comparison of AMG701 and AMG420 | - |
| OPPOSITION | - D32d-Sequence comparison of AMG701 and SEQ ID NO:700 of the Opposed Patent | - |
| OPPOSITION | - D34- Janeway et al., Garland Sci, 2001, figure 6.8 of antigen receptor sturcture and signaling pathways Immunobiology: The immune system in health and disease | - |
| OPPOSITION | - D36a-Teclistamab (INN 10928) | - |
| OPPOSITION | - D36b - Linvoseltamab (INN 12104) | - |
| OPPOSITION | - D36c - Elranatamab (INN 11838) | - |
| OPPOSITION | - D36d - Alnuctamab (INN 11457) | - |
| OPPOSITION | - D36e - Table of denominations of BCMA x CD3 bispecifc antibody constructs in clinical development at the priority date (internal names, INNs and product names | - |
| OPPOSITION | - D48- Amgen Inc Webcast Investor Meeting at ASH 2018 - Final © 2018 by CQ-Roll Call, Inc. All rights reserved. Presentation Provided by Factiva InC | - |
| OPPOSITION | - D4a- EP 19207293 (priority document of D4) | - |
| OPPOSITION | - D56-able extracted from the priority document (P1) of the Opposed Patent providing designations for sequences SEO ID NO: 1 to 71 | - |
| OPPOSITION | - D59-Abstract LB-299: Cynomolgus monkey plasma cell gene signature to quantify the in vivo activity of a half-life extended anti-BCMA BiTE® for the treatment of multiple myeloma | - |
| OPPOSITION | - D65-Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients:Updated results of a first-in-human (FIH) phase I dose escalation study | - |
| OPPOSITION | - D73-EudraCT Number: 2018-003188-78 | - |
| OPPOSITION | - D77-World Health Organization table of weight-for-age for boys aged 5 to 10 | - |
| OPPOSITION | - D78-Table of body surface area in children from the National Institute for Health and Care Excellence website | - |
| OPPOSITION | - D79a-Regeneron Archived Presentations | - |
| OPPOSITION | - D84-Proprietors’ submissions under Rule 116 EPC in EPO opposition proceedings relating to the Proprietors’ now-revoked EP 2 780 375 | - |
| OPPOSITION | - D85-Proprietors’ response to Appeal in proceedings relating to EP 2 155 783 | - |
| OPPOSITION | - D8a- US 62/865381 (priority document of D8) | - |
| OPPOSITION | - Einsele Hermann, Johannes Duell, Gerhard Zugmaier, Michel Attal, Philippe Moreau,Christian Langer, Jan Kronke, Thierry Facon, Alexey Salnikov, Robin Lesley, Karl Beutner, James Kalabus, Erik Rasmussen, Kathrin Riemann, Alex Minella,Gerd Munzert, Max Topp, "The anti-BCMA Bispecific T-cell Engager (BITE®) Molecule AMG 420 Induced MRD-Negative Complete Responses in R/R Multiple Myeloma in a FIH study", 17th International Myeloma Workshop, (20190901), pages e18 - e19, XP093241668 | - |
| OPPOSITION | - Helwick Caroline, "Bispecific Antibodies: Successes and Challenges", The ASCO Post, (20200410), pages 1 - 5, The ASCO Post, URL: https://ascopost.com/issues/april-10-2020/bispecific-antibodies-successes-and-challenges/, (20250121), XP093241687 | - |
| OPPOSITION | - Kontermann, Bispecific Antibodies, Berlin Heidelberg, Springer-Verlag, (20110101), doi:10.1007/978-3-642-20910-9, ISBN 978-3-642-20909-3 | - |
| OPPOSITION | - Lederman Lynne, "Anti-BCMA BiTE AMG 701 Shows Preclinical Promise in Multiple Myeloma", onclive, (20190916), pages 1 - 3, onclive, URL: https://www.onclive.com/view/antibcma-bite-amg-701-shows-preclinical-promise-in-multiple-myeloma, (20250121), XP093241557 | - |
| OPPOSITION | - Smith Eric, "DEVELOPMENT OF NOVEL FULLY HUMAN BISPECIFIC ANTIBODIES FOR ONCOLOGY", Regeneron, (20190410), pages 1 - 35, Regeneron, URL: https://newsroom.regeneron.com/static-files/2bdbbbac-f2bb-4c1f-b3be-55fac15eafca, (20250121), XP093241707 | - |
| OPPOSITION | - Taylor Nick Paul, "Amgen takes BiTEs out of pipeline, dropping BCMA, PSMA assets in light of data and competition", Fierce Biotec, (20220805), pages 1 - 1, Fierce Biotec, URL: https://www.fiercebiotech.com/biotech/amgen-takes-bites-out-pipeline-dropping-bcma-and-psma-assets-light-data-and-competition, (20250121), XP093241696 | - |
| OPPOSITION | - Rajshekhar Chakraborty; Navneet S. Majhail, "Treatment and disease‐related complications in multiple myeloma: Implications for survivorship", American Journal of Hematology, US , (20200313), vol. 95, no. 6, doi:10.1002/ajh.25764, ISSN 0361-8609, pages 672 - 690, XP071632805 | |
| OPPOSITION | - Ravi Gayathri, Costa Luciano J., "Bispecific T‐cell engagers for treatment of multiple myeloma", American journal of hematology, US , (20230301), vol. 98, no. S2, doi:10.1002/ajh.26628, ISSN 0361-8609, pages S13 - S21, XP093241227 | |
| OPPOSITION | - Yuraszeck T, Kasichayanula S, Benjamin J E, "Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment", Clinical Pharmacology and Therapeutics, US , (20170501), vol. 101, no. 5, doi:10.1002/cpt.651, ISSN 0009-9236, pages 634 - 645, XP093241710 | |
| OPPOSITION | - Lu Zheng, Rüdiger Kaspera, Yoichi Naritomi, Tianli Wang, "Dose Finding in Single Dose Studies by Allometric Scaling", Lu Zheng, Rüdiger Kaspera, Yoichi Naritomi, Tianli Wang, F.J. Hock, M.R. Gralinski, Drug Discovery and Evaluation: Methods in Clinical Pharmacology, Springer International Publishing AG , (20180101), pages 1 - 11, doi:10.1007/978-3-319-56637-5_3-1, XP093241656 | |
| OPPOSITION | - Gupta Vijayalaxmi; Bhavanasi Sneha; Quadir Mohiuddin; Singh Kevin; Ghosh Gaurav; Vasamreddy Kritin; Ghosh Arnab; Siahaan Teruna J.; Banerjee Snigdha; Banerjee Sushanta K., "Protein PEGylation for cancer therapy: bench to bedside", Journal of Cell Communication and Signaling, NL , (20181129), vol. 13, no. 3, doi:10.1007/s12079-018-0492-0, ISSN 1873-9601, pages 319 - 330, XP036881063 | |
| OPPOSITION | - Bittner Beate, Richter Wolfgang, Schmidt Johannes, "Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities", Biodrugs, NZ , (20181001), vol. 32, no. 5, doi:10.1007/s40259-018-0295-0, ISSN 1173-8804, pages 425 - 440, XP055884493 | |
| OPPOSITION | - Bittner Beate, Richter Wolfgang, Schmidt Johannes, "Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities", BioDrugs, NZ , (20181001), vol. 32, no. 5, doi:10.1007/s40259-018-0295-0, ISSN 1173-8804, pages 425 - 440, XP055884493 | |
| OPPOSITION | - Stein Anthony, Franklin Janet L., Chia Victoria M., Arrindell Deborah, Kormany William, Wright Jacqueline, Parson Mandy, Amouzadeh Hamid R., Choudhry Jessica, Joseph Guiandre, "Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia", Drug Safety, NZ , (20190501), vol. 42, no. 5, doi:10.1007/s40264-018-0760-1, ISSN 0114-5916, pages 587 - 601, XP093241649 | |
| OPPOSITION | - Xiaoying Chen, Jennica L. Zaro, Wei-Chiang Shen, "Fusion protein linkers: Property, design and functionality", NIH Public Access Author Manuscript, (20131001), doi:10.1016/j.addr.2012.09.039, pages 1 - 32, XP055341428 | |
| OPPOSITION | - Seckinger Anja; Delgado Jose Antonio; Moser Samuel; Moreno Laura; Neuber Brigitte; Grab Anna; Lipp Susanne; Merino Juana; Prosper Felipe; Emde Martina; Delon Camille; Latzko Melanie; Gianotti Reto; Lüoend Remo; Murr Ramona; Hosse Ralf J.; Harnisch Lydia Jasmin; Bacac Marina; Fauti Tanja; Klein Christian; Zabaleta Aintzane; Hillengass Jens; Cavalcanti-Adam Elisabetta Ada; Ho Anthony D.; Hundemer Michael; San Miguel Jesus F.; Strein Klaus; Umaña Pablo; Hose Dirk; Paiva Bruno; Vu Minh Diem, "Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment", Cancer cell, US , (20170302), vol. 31, no. 3, doi:10.1016/j.ccell.2017.02.002, ISSN 1535-6108, pages 396 - 410, XP029953443 | |
| OPPOSITION | - Crusoe Edvan De, Da Silva Ana Maria Marinho, Agareno Jozina, Chauffaille Maria De Lourdes, Bonfim Carmem, Moraes Hungria Vânia Tietsche, "Multiple Myeloma: A Rare Case in an 8-Year-Old Child", Clinical Lymphoma Myeloma and Leukemia, NL , (20150101), vol. 15, no. 1, doi:10.1016/j.clml.2014.08.004, ISSN 2152-2650, pages e31 - e33, XP093241699 | |
| OPPOSITION | - Steffen Dickopf, Georges Guy J., Brinkmann Ulrich, "Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies", Computational and structural biotechnology journal, Sweden , (20200514), vol. 18, doi:10.1016/j.csbj.2020.05.006, ISSN 2001-0370, pages 1221 - 1227, XP055740966 | |
| OPPOSITION | - Spiess Christoph; Zhai Qianting; Carter Paul J., "Alternative molecular formats and therapeutic applications for bispecific antibodies", Molecular Immunology, GB , (20150127), vol. 67, no. 2, doi:10.1016/j.molimm.2015.01.003, ISSN 0161-5890, pages 95 - 106, XP029246892 | |
| OPPOSITION | - Saber Haleh; Del Valle Pedro; Ricks Tiffany K.; Leighton John K., "An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection", Regulatory toxicology and pharmacology, US , (19000101), vol. 90, doi:10.1016/j.yrtph.2017.09.001, ISSN 0273-2300, pages 144 - 152, XP085227685 | |
| OPPOSITION | - Usmani Saad Z, Garfall Alfred L, Van De Donk Niels W C J, Nahi Hareth, San-Miguel Jesus F, Oriol Albert, Rosinol Laura, Chari Ajai, Bhutani Manisha, Karlin Lionel, Benboubker Lotfi, Pei Lixia, Verona Raluca, Girgis Suzette, Stephenson Tara, Elsayed Yusri, Infante Jeffrey, Goldberg Jenna D, Banerjee Arnob, Mateos María-Victoria, Krishnan Amrita, "Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study", The Lancet, AMSTERDAM, NL , (20210801), vol. 398, no. 10301, doi:10.1016/S0140-6736(21)01338-6, ISSN 0140-6736, pages 665 - 674, XP055951020 | |
| OPPOSITION | - Raab Marc S., Cohen Yael C., Schjesvold Fredrik, Aardalen Kimberly, Oka Adwait, Spencer Andrew, Wermke Martin, Souza Anita D., Kaufman Jonathan L., Cafro Anna Maria, Ocio Enrique M., Doki Noriko, Henson Kristin, Trabucco Gina, Carrion Ana, Bender Florent C., Juif Pierre-Eric, Fessehatsion Adonai, Fan Liqiong, Stonehouse Jeffrey P., Blankenship John W., Granda Brian, De Vita Serena, Lu Haihui, "Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody", Blood Cancer Journal, London, (20230601), vol. 37, no. 6, doi:10.1038/s41375-023-01883-3, ISSN 0887-6924, pages 1349 - 1360, XP093241080 | |
| OPPOSITION | - Bahlis Nizar J., Costello Caitlin L., Raje Noopur S., Levy Moshe Y., Dholaria Bhagirathbhai, Solh Melhem, Tomasson Michael H., Damore Michael A., Jiang Sibo, Basu Cynthia, Skoura Athanasia, Chan Edward M., Trudel Suzanne, Jakubowiak Andrzej, Gasparetto Cristina, Chu Michael P., Dalovisio Andrew, Sebag Michael, Lesokhin Alexander M., "Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial", Nature Medicine, New York, (20231001), vol. 29, no. 10, doi:10.1038/s41591-023-02589-w, ISSN 1078-8956, pages 2570 - 2576, XP093241076 | |
| OPPOSITION | - Foster Laahn H., Lum Lawrence G., "Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs", Expert opinion on biological therapy, (20190703), vol. 19, no. 7, doi:10.1080/14712598.2019.1604672, ISSN 1471-2598, pages 707 - 720, XP093123106 | |
| OPPOSITION | - Tai Yu-Tzu, Anderson Kenneth C, "B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma", Expert Opinion on Biological Therapy (Author manuscript), (20191101), vol. 19, no. 11, doi:10.1080/14712598.2019.1641196, ISSN 1471-2598, pages 1 - 27, XP093241161 | |
| OPPOSITION | - Ball Kathryn, Dovedi Simon J, Vajjah Pavan, Phipps Alex, "Strategies for clinical dose optimization of T cell-engaging therapies in oncology", mAbs, US , (20231231), vol. 15, no. 1, doi:10.1080/19420862.2023.2181016, ISSN 1942-0862, pages 1 - 18, XP093241178 | |
| OPPOSITION | - Clynes Raphael A, Desjarlais John R, "Annual Review of Medicine Redirected T Cell Cytotoxicity in Cancer Therapy", Annu. Rev. Med, (20181031), vol. 70, doi:10.1146/annurev-med-062617-, pages 437 - 50, XP093051050 | |
| OPPOSITION | - Tai Yu-Tzu; Mayes Patrick A; Acharya Chirag; Zhong Mike Y; Cea Michele; Cagnetta Antonia; Craigen Jenny; Yates John; Gliddon Louise; Fieles William; Hoang Bao; Tunstead James; Christie Amanda L; Kung Andrew L; Richardson Paul; Munshi Nikhil C; Anderson Kenneth C, "Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma", Blood, US , (20140515), vol. 123, no. 20, doi:10.1182/blood-2013-10-535088, ISSN 0006-4971, pages 3128 - 3138, XP009505860 | |
| OPPOSITION | - Topp Max S; Duell Johannes; Zugmaier Gerhard; Attal Michel; Moreau Philippe; Langer Christian; Kroenke Jan; Facon Thierry; Einsele Hermann; Munzert Gerd, "Treatment with AMG 420, an Anti-B-CellMaturationAntigen (BCMA) Bispecific T-Cell Engager (BiTE (R)) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study", Blood, US , (20181129), vol. 132, no. Suppl. 1, doi:10.1182/blood-2018-99-109769, ISSN 0006-4971, pages 1 - 5, XP009519963 | |
| OPPOSITION | - Lesokhin Alexander M.; Raje Noopur; Gasparetto Cristina J; Walker Justine; Krupka Heike I.; Joh Tenshang; Taylor Carrie T.; Jakubowiak Andrzej, "A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma", Blood, US , (20181129), vol. 132, doi:10.1182/blood-2018-99-110427, ISSN 0006-4971, page 3229, XP086591928 | |
| OPPOSITION | - Costa Luciano J.; Wong Sandy W.; Bermudez Arancha; de la Rubia Javier; Mateos Maria-Victoria; Ocio Enrique M.; Rodriguez-Otero Paula; San-Miguel Jesus; Li Shaoyi; Sarmiento Rafael; Lardelli Pilar; Gaudy Allison; Boss Isaac; Kelly Lisa M.; Burgess Michael R.; Hege Kristen; Bensinger William I., "First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial", Blood, US , (20191113), vol. 134, doi:10.1182/blood-2019-122895, ISSN 0006-4971, pages 1 - 5, XP086665034 | |
| OPPOSITION | - Cooper Dennis; Madduri Deepu; Lentzsch Suzanne; Jagannath Sundar; Li Jingjin; Boyapati Anita; Adriaens Lieve; Chokshi Dhruti; Zhu Min; Lowy Israel; Weinreich David M.; Yancopoulos George D.; Sharma Manish; Karasarides Maria; Sternberg David, "Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma", Blood, US , (20191113), vol. 134, doi:10.1182/blood-2019-126818, ISSN 0006-4971, pages 1 - 4, XP086663599 | |
| OPPOSITION | - Harrison Simon J, Minnema Monique C., Lee Hans C., Spencer Andrew, Kapoor Prashant, Madduri Deepu, Larsen Jeremy, Ailawadhi Sikander, Kaufman Jonathan L., Raab Marc S., Hari Parameswaran, Iida Shinsuke, Vij Ravi, Davies Faith E., Lesley Robin, Upreti Vijay V., Yang Zhao, Sharma Anjali, Minella Alex, Lentzsch Suzanne, "A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)", Blood, American Society of Hematology, US , (20201105), vol. 136, no. Supplement 1, doi:10.1182/blood-2020-134063, ISSN 0006-4971, pages 28 - 29, XP055893178 | |
| OPPOSITION | - Goldstein Rebecca L., Goyos Ana, Li Chi-Ming, Deegen Petra, Bogner Pamela, Sternjak Alexander, Thomas Oliver, Klinger Matthias, Wahl Joachim, Friedrich Matthias, Rattel Benno, Lamas Edwin, Min Xiaoshan, Sudom Athena, Farshbaf Mozhgan, Coxon Angela, Balazs Mercedesz, Arvedson Tara, "AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys", Blood Advances, (20200908), vol. 4, no. 17, doi:10.1182/bloodadvances.2020002565, ISSN 2473-9529, pages 4180 - 4194, XP093241204 | |
| OPPOSITION | - Bumma Naresh, Richter Joshua, Jagannath Sundar, Lee Hans C., Hoffman James E., Suvannasankha Attaya, Zonder Jeffrey A., Shah Mansi R., Lentzsch Suzanne, Baz Rachid, Maly Joseph J., Namburi Swathi, Pianko Matthew J., Ye Jing Christine, Wu Ka Lung, Silbermann Rebecca, Min Chang-Ki, Vekemans Marie-Christiane, Munder Markus, Byun Ja Min, Martínez-Lopez Joaquín, Cassady Kaniel, Deveaux Michelle, Chokshi Dhruti, Boyapati Anita, Hazra Anasuya, Yancopoulos George D., Sirulnik L. Andres, Rodriguez Lorenc Karen, Kroog Glenn S., Houvras Yariv, Dhodapkar Madhav V., "Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma", Journal of Clinical Oncology, (20240801), vol. 42, no. 22, doi:10.1200/JCO.24.01008, ISSN 0732-183X, pages 2702 - 2712, XP093241519 | |
| OPPOSITION | - Eckhert Erik, Hewitt Rhonda, Liedtke Michaela, "B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma", Immunotherapy, UK, (20190501), vol. 11, no. 9, doi:10.2217/imt-2018-0199, ISSN 1750-743X, pages 801 - 811, XP009527380 | |
| OPPOSITION | - Caraccio Chiara, Krishna Sachi, Phillips Darci J., Schürch Christian M., "Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions", Frontiers in Immunology, Lausanne, CH , (20200424), vol. 11, doi:10.3389/fimmu.2020.00501, ISSN 1664-3224, pages 1 - 25, XP055860851 | |
| OPPOSITION | - Strohl William R, Naso, M, "Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells", Antibodies, (20190703), vol. 8, no. 3, doi:10.3390/antib8030041, pages 1 - 68, XP055935197 | |
| OPPOSITION | - Dalla Palma Benedetta, Marchica Valentina, Catarozzo Maria Teresa, Giuliani Nicola, Accardi Fabrizio, "Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma", Journal of Clinical Medicine, CH , (20200101), vol. 9, no. 9, doi:10.3390/jcm9093022, ISSN 2077-0383, pages 1 - 11, XP093241528 | |
| OPPOSITION | - Trabolsi Asaad, Arumov Artavazd, Schatz Jonathan H., "T Cell-Activating Bispecific Antibodies in Cancer Therapy", Journal of Immunology, (20190801), vol. 203, no. 3, doi:10.4049/jimmunol.1900496, ISSN 0022-1767, pages 585 - 592, XP055812112 | |
| OPPOSITION | - Anroopb Nair, Shery Jacob, "A simple practice guide for dose conversion between animals and human", Journal of Basic and Clinical Pharmacy, India , (20160501), vol. 7, no. 2, doi:10.4103/0976-0105.177703, ISSN 0976-0105, page 27, XP055407475 | |
